Abstract Details

Title Improvements in Quality of Life Over 6 Years in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Alemtuzumab: Results From the CARE-MS II Extension Study

Topic Multiple Sclerosis

Presentation(s) P5 - (-)

Poster/Presentation
Number 342

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Rafael Arroyo Gonzalez PRESENTER	Rafael Arroyo Gonzalez has nothing to disclose.
David H. Margolin, MD, PhD (Genzyme Corporation)	Dr. Margolin has received personal compensation for serving as an employee of Cerevance, Inc. Dr. Margolin has received personal compensation in the range of $0-$499 for serving as a Consultant for Datacubed Health. Dr. Margolin has received stock or an ownership interest from Cerevance, Inc. Dr. Margolin has received stock or an ownership interest from Datacubed Health. Dr. Margolin has received intellectual property interests from a discovery or technology relating to health care.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Jennifer Guo (Sanofi)	No disclosure on file
David Cella, PhD (Northwestern Feinberg School of Medicine)	No disclosure on file
	No disclosure on file